BRCA2 and ovarian serous adenocarcinoma: Finally, in a study among 103 patients with serous ovarian cancer (21 BRCA1-mutated, 10 BRCA2-mutated, 21 BRCA1 methylation, and 51 no BRCA loss), BRCA-mutated tumors tended to be more frequently infiltrated by CD8+ T cells (92.9%) as compared to tumors with BRCA1 methylation (76.2%) or no BRCA loss (73.9%, p = 0.057) [58].